European Archives - European Medical Journal

HFpEF

Hidden HFpEF Prevalence Found in INOCA Patients

Notably, the HFpEF prevalence in this INOCA group reached 35.29%, meaning over one-third of patients met established diagnostic criteria.

Fountain pen signing a contract

Promotion of biologics under fire from FDA

The recent FDA letters to four biologics companies signal a continued rise in enforcement activity.

Patrica-Ganz---Web

Onc Now: Rethinking Life After Cancer

In this episode of Onc Now, Patricia Ganz sits down with EMJ to explore the evolving field of cancer survivorship….

CKD Biomarkers Improve Personalised Treatment Strategies - EMJ

New Urinary Biomarkers May Refine CKD Risk Stratification

Novel urinary biomarkers could improve CKD risk stratification by capturing tubular injury and repair beyond traditional albuminuria measures.

Severe Infections Tied to Increased Dementia Risk

Severe infections are linked to a higher dementia risk: researchers found that people with cystitis have a more than 20% increased risk.

Experts Urge Global Recognition of AI as Public Mental Health Concern

WHO has recommended that generative AI use must be recognised as a public mental health concern, flagging concern over its growing use for emotional support among young people.

bleeding risk

Apixaban Shows Lower Bleeding Risk In VTE

Apixaban significantly reduces bleeding risk compared with rivaroxaban in acute venous thromboembolism, based on data from a large international randomised trial.

Earlier Biologics for Improved Outcomes in Generalised Myasthenia Gravis

Lünemann described gMG as a complex chronic autoimmune disease that can be managed but not yet cured.1 Standard…

Chlormethine Gel Reshapes the Tumour Microenvironment in Mycosis Fungoides

Cutaneous T cell lymphomas (CTCL) are a heterogenous group of rare malignancies primarily involving the skin, of which mycosis fungoides…

Two people shaking hands

Lilly and Insilico strike historic $2.75bn AI alliance

The collaboration marks one of the largest generative AI-driven partnerships in the pharmaceutical industry to date.